Investor Overview

Corporate Summary

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

  • Pending merger with Cend Therapeutics, creating Lisata Therapeutics, which will be a financially sound publicly-traded company with clinical stage product candidates
  • Combination of Caladrius and Cend platforms provides Lisata with a multi-product development pipeline
  • Proprietary field-leading technology in lucrative global indications backed by a strong IP portfolio
  • Potential value creating events in the next 12-24 months based on milestones across the pipeline
  • Strong balance sheet [$88.5 million cash & investments (as of 3/31/2022) - no debt]; well-positioned for current development programs’ projected capital needs and cash balance target at merger closing
  • Seasoned management with domain expertise along with big pharma and emerging biotech experience